Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Encouraging outcomes for Rituxan phase II and III trials

Dec. 11, 2003

hTERT-based vaccine approaches to breast cancer

Dec. 10, 2003

MLN-2704 granted fast track designation

Dec. 9, 2003

Antitumor effects of the HLA-DR-specific MAb 1D09C3 shown in vitro and in vivo

Dec. 9, 2003

Cetuximab enhances antitumor effects of cisplatin in late-stage clinical trial

Nov. 27, 2003

Medarex given go-ahead to begin phase I/II trial of MDX-214

Nov. 26, 2003

FDA lifts partial clinical hold on phase III trials of Oncophage

Nov. 26, 2003

Shionogi describes GM-CSF-like compounds with potential in cancer and neutropenia

Nov. 25, 2003

Therion evaluates Prostvac-VF in new phase II prostate cancer study

Nov. 25, 2003

Increased antitumor activity of pertuzumab combined with cytotoxic drugs in NSCLC models

Nov. 25, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...